BRPI0412382A - composto , método para a verificação de novos compostos medicinais que se ligam a e modulam a atividade, por agonismo , agonismo parcial, ou antagonismo, do receptor de acetilcolina nicotìnico alfa7, método de tratamento ou profilaxia de uma doença ou condição humana, método para tratamento de jetlag, induzindo interrupção de fumar, vìcio em nicotina, abstinência, dor, e para colite ulcerativa, composição farmacêutica, e, método de tratamento ou prevenção de uma condição ou distúrbio que surge da disfunção de neurotransmissão do receptor de acetilcolina nicotìnico em um mamìfero, e, uso de um composto - Google Patents
composto , método para a verificação de novos compostos medicinais que se ligam a e modulam a atividade, por agonismo , agonismo parcial, ou antagonismo, do receptor de acetilcolina nicotìnico alfa7, método de tratamento ou profilaxia de uma doença ou condição humana, método para tratamento de jetlag, induzindo interrupção de fumar, vìcio em nicotina, abstinência, dor, e para colite ulcerativa, composição farmacêutica, e, método de tratamento ou prevenção de uma condição ou distúrbio que surge da disfunção de neurotransmissão do receptor de acetilcolina nicotìnico em um mamìfero, e, uso de um compostoInfo
- Publication number
- BRPI0412382A BRPI0412382A BRPI0412382-4A BRPI0412382A BRPI0412382A BR PI0412382 A BRPI0412382 A BR PI0412382A BR PI0412382 A BRPI0412382 A BR PI0412382A BR PI0412382 A BRPI0412382 A BR PI0412382A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- compound
- condition
- agonism
- acetylcholine receptor
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 9
- 150000001875 compounds Chemical class 0.000 title abstract 8
- 238000011282 treatment Methods 0.000 title abstract 6
- 230000008484 agonism Effects 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 title abstract 2
- 206010009900 Colitis ulcerative Diseases 0.000 title abstract 2
- 208000001456 Jet Lag Syndrome Diseases 0.000 title abstract 2
- 201000006704 Ulcerative Colitis Diseases 0.000 title abstract 2
- 230000008485 antagonism Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 230000001939 inductive effect Effects 0.000 title abstract 2
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 title abstract 2
- 108010009685 Cholinergic Receptors Proteins 0.000 title 1
- 241000124008 Mammalia Species 0.000 title 1
- 206010057852 Nicotine dependence Diseases 0.000 title 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 title 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 title 1
- 208000025569 Tobacco Use disease Diseases 0.000 title 1
- 102000034337 acetylcholine receptors Human genes 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 230000004064 dysfunction Effects 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 230000005586 smoking cessation Effects 0.000 title 1
- 230000005062 synaptic transmission Effects 0.000 title 1
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
- 206010012335 Dependence Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229960002715 nicotine Drugs 0.000 abstract 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000000391 smoking effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48552303P | 2003-07-08 | 2003-07-08 | |
| PCT/GB2004/002904 WO2005005435A1 (en) | 2003-07-08 | 2004-07-06 | Spiro ′1-azabicyclo ′2.2.2!octan-3,5′-oxazolidin -2′-one! derivatives with affinity to the alpha7 nicotinic acetylcholine receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0412382A true BRPI0412382A (pt) | 2006-09-19 |
Family
ID=34062082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0412382-4A BRPI0412382A (pt) | 2003-07-08 | 2004-07-06 | composto , método para a verificação de novos compostos medicinais que se ligam a e modulam a atividade, por agonismo , agonismo parcial, ou antagonismo, do receptor de acetilcolina nicotìnico alfa7, método de tratamento ou profilaxia de uma doença ou condição humana, método para tratamento de jetlag, induzindo interrupção de fumar, vìcio em nicotina, abstinência, dor, e para colite ulcerativa, composição farmacêutica, e, método de tratamento ou prevenção de uma condição ou distúrbio que surge da disfunção de neurotransmissão do receptor de acetilcolina nicotìnico em um mamìfero, e, uso de um composto |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7514567B2 (https=) |
| EP (1) | EP1654264A1 (https=) |
| JP (1) | JP2007516200A (https=) |
| KR (1) | KR20060057569A (https=) |
| CN (1) | CN1829721A (https=) |
| AR (1) | AR045040A1 (https=) |
| AU (1) | AU2004255920B2 (https=) |
| BR (1) | BRPI0412382A (https=) |
| CA (1) | CA2531510A1 (https=) |
| IL (1) | IL172762A0 (https=) |
| MX (1) | MXPA06000231A (https=) |
| NO (1) | NO20060612L (https=) |
| NZ (1) | NZ545132A (https=) |
| SA (1) | SA04250212B1 (https=) |
| TW (1) | TW200524942A (https=) |
| WO (1) | WO2005005435A1 (https=) |
| ZA (1) | ZA200600154B (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070090922A (ko) * | 2004-12-15 | 2007-09-06 | 아스트라제네카 아베 | 니코틴성 아세틸콜린 수용체 리간드 |
| US7649007B2 (en) | 2006-08-15 | 2010-01-19 | Wyeth Llc | Oxazolidine derivatives as PR modulators |
| TW200815428A (en) | 2006-08-15 | 2008-04-01 | Wyeth Corp | Oxazolidone derivatives as PR modulators |
| US7618989B2 (en) | 2006-08-15 | 2009-11-17 | Wyeth | Tricyclic oxazolidone derivatives useful as PR modulators |
| WO2008021309A1 (en) | 2006-08-15 | 2008-02-21 | Wyeth | Imidazolidin-2-one derivatives useful as pr modulators |
| WO2008021337A1 (en) * | 2006-08-15 | 2008-02-21 | Wyeth | Oxazinan-2-one derivatives useful as pr modulators |
| JP2010505844A (ja) * | 2006-10-03 | 2010-02-25 | ガレオン・フアーマシユーチカルズ・インコーポレーテツド | Ｓ−ニトロソチオール化合物および関連誘導体 |
| SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| US7863291B2 (en) * | 2008-04-23 | 2011-01-04 | Bristol-Myers Squibb Company | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| US8309577B2 (en) | 2008-04-23 | 2012-11-13 | Bristol-Myers Squibb Company | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands |
| EP2586311B1 (de) * | 2008-07-17 | 2016-12-14 | Bayer CropScience AG | Heterocyclische Verbindungen als Schädlingsbekämpfungsmittel |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| UA107791C2 (en) * | 2009-05-05 | 2015-02-25 | Dow Agrosciences Llc | Pesticidal compositions |
| US8759550B2 (en) | 2009-08-27 | 2014-06-24 | Yeda Research And Development Co. Ltd. | Oligo- and polyfurans, preparation and uses thereof |
| US8278320B2 (en) | 2009-10-28 | 2012-10-02 | Bristol-Myers Squibb Company | Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| US8507516B2 (en) | 2009-10-28 | 2013-08-13 | Bristol-Myers Squibb Company | Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| EP2558458B1 (de) | 2010-04-16 | 2017-09-06 | Bayer Intellectual Property GmbH | Neue heterocyclische verbindungen als schädlingsbekämpfungsmittel |
| CN103025744A (zh) | 2010-04-30 | 2013-04-03 | 百时美施贵宝公司 | 作为α-7烟碱乙酰胆碱受体配体前药的氮杂二环胺N-氧化物化合物 |
| EP2595983A1 (en) | 2010-07-22 | 2013-05-29 | Novartis AG | 2,3,5-trisubstituted thiophene compounds and uses thereof |
| WO2012052412A1 (de) | 2010-10-22 | 2012-04-26 | Bayer Cropscience Ag | Neue heterocylische verbindungen als schädlingsbekämpfungsmittel |
| KR20140138293A (ko) | 2012-03-16 | 2014-12-03 | 액시킨 파마수티컬스 인코포레이티드 | 3,5-다이아미노피라졸 키나아제 억제제 |
| CN104884449A (zh) | 2012-10-31 | 2015-09-02 | 拜尔农作物科学股份公司 | 作为害虫防治剂的新的杂环化合物 |
| NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
| US9546163B2 (en) | 2014-12-23 | 2017-01-17 | Axikin Pharmaceuticals, Inc. | 3,5-diaminopyrazole kinase inhibitors |
| EA202092441A1 (ru) | 2016-06-07 | 2021-05-21 | Джакобио Фармасьютикалс Ко., Лтд. | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 |
| KR20240026521A (ko) | 2017-03-23 | 2024-02-28 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
| CN112839935A (zh) | 2018-09-26 | 2021-05-25 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4855290A (en) * | 1985-05-10 | 1989-08-08 | State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research | Derivatives of quinuclidine |
| JP3708962B2 (ja) * | 1994-08-24 | 2005-10-19 | アストラゼネカ・アクチエボラーグ | 治療に有用なスピロ−アザ二環式化合物 |
| WO2001066546A1 (en) * | 2000-03-09 | 2001-09-13 | Mitsubishi Pharma Corporation | Spiro compounds, process for preparing the same and use thereof as drugs |
-
2004
- 2004-07-06 CN CNA2004800218491A patent/CN1829721A/zh active Pending
- 2004-07-06 KR KR1020067000400A patent/KR20060057569A/ko not_active Ceased
- 2004-07-06 EP EP04743249A patent/EP1654264A1/en not_active Withdrawn
- 2004-07-06 AU AU2004255920A patent/AU2004255920B2/en not_active Ceased
- 2004-07-06 JP JP2006518343A patent/JP2007516200A/ja active Pending
- 2004-07-06 WO PCT/GB2004/002904 patent/WO2005005435A1/en not_active Ceased
- 2004-07-06 NZ NZ545132A patent/NZ545132A/en unknown
- 2004-07-06 BR BRPI0412382-4A patent/BRPI0412382A/pt not_active IP Right Cessation
- 2004-07-06 CA CA002531510A patent/CA2531510A1/en not_active Abandoned
- 2004-07-06 MX MXPA06000231A patent/MXPA06000231A/es active IP Right Grant
- 2004-07-06 US US10/563,271 patent/US7514567B2/en not_active Expired - Fee Related
- 2004-07-07 AR ARP040102394A patent/AR045040A1/es not_active Application Discontinuation
- 2004-07-08 TW TW093120518A patent/TW200524942A/zh unknown
- 2004-07-11 SA SA04250212A patent/SA04250212B1/ar unknown
-
2005
- 2005-12-22 IL IL172762A patent/IL172762A0/en unknown
-
2006
- 2006-01-06 ZA ZA200600154A patent/ZA200600154B/en unknown
- 2006-02-08 NO NO20060612A patent/NO20060612L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004255920A1 (en) | 2005-01-20 |
| JP2007516200A (ja) | 2007-06-21 |
| CN1829721A (zh) | 2006-09-06 |
| KR20060057569A (ko) | 2006-05-26 |
| AU2004255920B2 (en) | 2008-05-15 |
| IL172762A0 (en) | 2006-04-10 |
| WO2005005435A1 (en) | 2005-01-20 |
| NO20060612L (no) | 2006-04-06 |
| TW200524942A (en) | 2005-08-01 |
| AR045040A1 (es) | 2005-10-12 |
| ZA200600154B (en) | 2007-04-25 |
| MXPA06000231A (es) | 2006-04-11 |
| SA04250212B1 (ar) | 2009-08-11 |
| NZ545132A (en) | 2009-07-31 |
| CA2531510A1 (en) | 2005-01-20 |
| US20060154945A1 (en) | 2006-07-13 |
| US7514567B2 (en) | 2009-04-07 |
| EP1654264A1 (en) | 2006-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0412382A (pt) | composto , método para a verificação de novos compostos medicinais que se ligam a e modulam a atividade, por agonismo , agonismo parcial, ou antagonismo, do receptor de acetilcolina nicotìnico alfa7, método de tratamento ou profilaxia de uma doença ou condição humana, método para tratamento de jetlag, induzindo interrupção de fumar, vìcio em nicotina, abstinência, dor, e para colite ulcerativa, composição farmacêutica, e, método de tratamento ou prevenção de uma condição ou distúrbio que surge da disfunção de neurotransmissão do receptor de acetilcolina nicotìnico em um mamìfero, e, uso de um composto | |
| Gavalda et al. | Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile | |
| D Levin | α7-Nicotinic receptors and cognition | |
| JP5698282B2 (ja) | 痛みの治療のための混合されたＯＲＬ１／μ−アゴニスト | |
| Horak et al. | The pharmacology of tacrine at N-methyl-d-aspartate receptors | |
| UA86614C2 (ru) | Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата | |
| PT1102588E (pt) | Composições farmacêuticas para a prevenção e tratamento de distúrbios no sistema nervoso central que compreendem um análogo de nicotina e um inibidor de acetilcolinesterase | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| JP2002532393A (ja) | エキソ−ｒ−メカミラミン製剤および治療におけるその使用 | |
| JP5208473B2 (ja) | アゼラスチンと抗コリン薬を含有する医薬組成物 | |
| EA200970706A1 (ru) | Новые фармацевтические композиции | |
| EA200970435A1 (ru) | Лечение общих расстройств развития | |
| WO2012007159A3 (en) | Novel gastro-retentive dosage forms | |
| BR0316364A (pt) | Combinação de terapia do câncer com um composto anticâncer ativado com gst e uma outra terapia anticâncer | |
| BRPI0509777A (pt) | composto, métodos de tratamento ou profilaxia de doenças ou condições e de distúrbios, método para induzir o parar de fumar, composição farmacêutica, e, uso de um composto,um enantiÈmero do mesmo ou um sal farmaceuticamente aceitável do mesmo | |
| Choi et al. | Effects of ginsenosides, active components of ginseng, on nicotinic acetylcholine receptors expressed in Xenopus oocytes | |
| BRPI0413693A (pt) | composição farmacêutica para a prevenção e tratamento da viciação em um mamìfero | |
| BR0313718A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto | |
| UY31417A1 (es) | Una composicion farmacéutica y un proceso para dicha composicion farmacéutica | |
| BRPI0506881A (pt) | derivado de arila diazabicìclica, composição farmacêutica, uso de um derivado de arila diazabicìclica, e, método de tratamento, prevenção ou alìvio de uma doença ou distúrbio ou condição de um corpo de animal vivo | |
| BRPI0409796A (pt) | uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina | |
| BRPI0519280A2 (pt) | composto, composiÇço farmacÊutica e uso de um composto | |
| BR0314183A (pt) | Derivados de 1,4-diazabicicloalcano, quaisquer de seus enanciÈmeros ou qualquer mistura de seus enaciÈmeros, ou um seu sal de adição farmaceuticamente aceitável ou um seu n-óxido, composição farmacêutica, uso do dito composto, de qualquer um de seus enanciÈmeros ou de qualquer mistura de seus enanciÈmeros, ou de um seu sal de adição farmaceuticamente aceitável, e, método de tratamento, prevenção ou alìvio de uma doença ou um distúrbio ou condição de um corpo animal vivo | |
| Chellian et al. | Alpha-asarone attenuates depression-like behavior in nicotine-withdrawn mice: evidence for the modulation of hippocampal pCREB levels during nicotine-withdrawal | |
| BRPI0411608A (pt) | derivado de 8-aza-biciclo [3.2.1] octano, composição farmacêutica, uso do composto, e, método de tratamento, prevenção ou alìvio de uma doença, um distúrbio ou uma condição de um organismo animal vivo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |